APA (7th ed.) Citation

Facheris, P., Piscazzi, F., Fiorillo, G., Valenti, M., Costanzo, A., & Borroni, R. G. (2026). Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study. Dermatology & Therapy, 16(6), 3027. https://doi.org/10.1007/s13555-026-01760-8

Chicago Style (17th ed.) Citation

Facheris, Paola, Francesco Piscazzi, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, and Riccardo G. Borroni. "Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study." Dermatology & Therapy 16, no. 6 (2026): 3027. https://doi.org/10.1007/s13555-026-01760-8.

MLA (9th ed.) Citation

Facheris, Paola, et al. "Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study." Dermatology & Therapy, vol. 16, no. 6, 2026, p. 3027, https://doi.org/10.1007/s13555-026-01760-8.